Murine model of ferric chloride-induced vena cava thrombosis: Evidence for effect of potato carboxypeptidase inhibitor

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 403-410

  Wang, Xinkang ^a   Smith, P L ^a   Hsu, M Y ^a   Ogletree, M L ^a   Schumacher, W A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Arterial thrombosis; Bleeding time; Hemostasis; Mouse; PCI; TAFI; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FERRIC CHLORIDE; HEPARIN; PEPTIDE HYDROLASE INHIBITOR; POTATO CARBOXYPEPTIDASE INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE INHIBITOR, PLANT; FERRIC ION; FIBRINOLYTIC AGENT; PROTEINASE INHIBITOR; VEGETABLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; CAROTID ARTERY THROMBOSIS; CAVA VEIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EVIDENCE BASED MEDICINE; EX VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; RODENT; TAIL; THROMBOELASTOGRAPHY; THROMBOSIS; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; IN VITRO STUDY; POTATO; VEIN THROMBOSIS;

ANIMALS; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PLANT PROTEINS; PROTEASE INHIBITORS; SOLANUM TUBEROSUM; THROMBOLYTIC THERAPY; VENAE CAVAE; VENOUS THROMBOSIS;

EID: 33645563991     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01703.x     Document Type: Article

References (34)

1. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1: 1566-74.
2. Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004; 11: 2335-48.
3. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
4. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
5. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.
6. Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, Aznar J, Estelles A. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-65.
7. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-40.
8. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
9. Ryan CA, Hass GM, Kuhn RW. Purification and properties of a carboxypeptidase inhibitor from potatoes. J Biol Chem 1974; 249: 5495-9.
10. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
11. Muto Y, Suzuki K, Sato E, Ishii H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003; 461: 181-9.
12. Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S, Ishii H. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2- [(R)-2-methyl-1-(3-phenylpropanoy lamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004; 309: 607-15.
13. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem 2003; 46: 5294-7.
14. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze Jr GJ, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
15. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
16. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu M-Y, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
17. Meh DA, Mosesson MW, DiOrio JP, Siebenlist KR, Hernandez I, Amrani DL, Stojanovich L. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coag Fibrinolysis 2001; 12: 627-37.
18. Georgopapadakou NH, Liu FY, Ryono DE, Neubeck R, Gordon EM, Pluscec J. Streptomyces R61 DD-carboxypeptidase: Hydrolysis of X-D-alanyl-D-alanine peptides measured by a fluorometric assay. Anal Biochem 1984; 137: 125-8.
19. Wentland MP, Raza S, Gao Y. 96-well plate colorimetric assay for Ki determination of (±)-2-benzylsuccinic acid, an inhibitor of carboxypeptidase A: A laboratory experiment in drug discovery. J Chem Educ 2004; 81: 398-400.
20. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
21. Day SM, Reeve JL, Myers DD, Fay WP. Murine thrombosis models. Thromb Haemost 2004; 92: 486-94.
22. Carlsson S, Elg M. The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. Blood Coagul Fibrinolysis 2005; 16: 245-9.
23. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9.
24. Elg M, Gustafsson D, Carlsson D. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97.
25. Smyth SS, Reis ED, Vaananen H, Zhang W, Coller BS. Variable protection of β 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 2001; 98: 1055-62.
26. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood 2002; 100: 3240-4.
27. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996; 156: 1645-9.
28. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
29. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-6.
30. Millet J, Theveniaux J, Pascal M. A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations. Thromb Res 1987; 45: 123-33.
31. Wang X, Xu L, Wang H, Grzanna R, Zhan Y, Knabb RM, Luettgen JM, Bozarth TA, Galemmo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ. Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. Stroke 2003; 34: 468-74.
32. Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization vs. inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 8913-21.
33. Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1: 147-54.
34. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.